In an interview with BIO Buzz, Kenneth Kelley, PaxVax CEO, discusses how PaxVax is differentiating itself from other biotechnology companies and vaccine multinational companies as well as the company’s one-dose, oral cholera vaccine in development.
Kenneth Kelley, PaxVax CEO, writes about PaxVax’s double bottom line. The company explores all available avenues to funding and capital efficiency, while keeping investors satisfied with both financial and social returns.
Clinical trial management works to improve efficiencies, gain increased patient and investigator access, and better integrate R&D capabilities and solutions.
PaxVax prepares fast-acting cholera vaccine, PXVX-0200, for Phase III trials and influenza vaccine, H5N1, for Phase II trials.
The U.S. FDA accepts investigational new drug (IND) application from PaxVax for single-dose, oral cholera vaccine.
The U.S. government invests in vaccine production technology to provide alternative flu vaccines that can be developed and delivered efficiently in the presence of biological threats.
The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health announces the decision to fund research on three vaccines to protect against emerging infectious diseases and biological threats.